Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
Gilead Ignored HIV Groups Before Failed Bid To Have PrEP Subsidised In Australia

A drug manufacturer failed to take the advice of top HIV/AIDS organisations when it made a submission for a highly effective HIV prevention drug to be subsidised by the government, those organisations say.

Published
25 August 2016
From
BuzzFeed
Having Sex With Poz Men Helped Kick My Fear of HIV

The fear of contracting HIV has run my life for what feels like forever, and I’m not willing to let it control me any longer.

Published
23 August 2016
From
The Advocate
European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada® For Reducing the Risk of Sexually Acquired HIV-1

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for once-daily Truvada® (emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) in combination with safer-sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy known as pre-exposure prophylaxis, or PrEP.

Published
22 August 2016
From
Gilead press release
Make your voice heard on PrEP in England – take part in the PrEP public consultation

PrEPster, along with NAT and THT, and other organisations in the United4PrEP coalition is urging individuals and institutions to take part in the NHS England PrEP consultation. The results from the consultation will be considered by the NHS England committee (CPAG) that makes the final decision on PrEP. Together, we’ve produced toolkits that assist individuals and organisations in responding to the consultation, along with sample responses.

Published
22 August 2016
From
Prepster
HIV prevention drug Truvada won't be subsidised in Australia

Truvada, an expensive breakthrough drug that prevents people from getting HIV won't be funded by taxpayers in Australia this year, the nation's drug funding panel has ruled. A Department of Health spokeswoman said the PBAC understood "this is an important new prevention medication for HIV", but decided the price set by the drug's sponsor, Gilead Sciences, was too high and a proposal to limit subsidy to a small subset of the "at risk" group was not feasible. "In its deliberations the PBAC indicated a substantial price reduction would be needed to make Truvada available for PrEP for the whole 'at risk' population, but noted that Truvada for PrEP could represent value for money in the broader population at a substantially lower price," the spokeswoman said.

Published
19 August 2016
From
Sydney Morning Herald
Have your say on PrEP – Londoners urged to voice their opinions

Londoners are being urged to share their views and opinions on PrEP with NHS England. Councillor Teresa O’Neill OBE, London Councils’ Executive member for health, stressed the importance of Londoners sharing their views as a large portion of those living with HIV reside in the capital. “We are concerned that NHS England, by arguing it is not responsible for funding PrEP, is trying to shift costs to local authorities."

Published
16 August 2016
From
Gay Times
Are we 'Generation Bareback'?

Recent studies show an increase in unprotected sex amongst HIV-negative gay men. Why are some of us ditching condoms? And in a world of treatment, undetectability and PrEP, is this the start of generation bareback?

Published
15 August 2016
From
FS
Mike Freer: Evaluating this anti-HIV drug should be based on clinical effectiveness – not prejudice over life choices

If we can fund the contraceptive pill, we can fund PrEP. Funding for drugs should only ever be based on clinical evaluation, cost effectiveness and the impact on society more widely. Each one of those criteria have been met in my mind, and for this reason NHS England should move in the direction of funding PrEP.

Published
15 August 2016
From
Conservative Home
Vaginal bacteria increase HIV susceptibility and may reduce PrEP effectiveness

Overgrowth of a certain species of vaginal bacteria was associated with a 13-fold higher likelihood of acquiring HIV, while another species was found to lower tenofovir levels

Published
15 August 2016
By
Liz Highleyman
Why Doesn’t NHS England Want to Be Responsible for Preventing HIV?

In March 2015, Simon Stevens, Chief Executive of NHS England, announced the first national diabetes prevention programme. Reflecting on the potential for the NHS to reduce the future costs of diabetes care by supporting people to lose weight, exercise and eat better, he said that "if these results were from a pill we'd doubtless be popping it".

Published
11 August 2016
From
National AIDS Trust
← First12345...93Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close